acbd6 Antibody

What is ACBD6 and why is it significant in research applications?

ACBD6 (Acyl-CoA Binding Domain Containing 6) is a protein that controls acyl chain availability and specificity in cellular processes. Its significance stems from its ability to promote N-myristoylation under substrate-limiting conditions. Research has demonstrated that ACBD6 stimulates the activity of myristoyltransferases (NMTs) and protects them from inhibition by competing acyl-CoA species, particularly C16-CoA . The protein contains an acyl-CoA binding domain with notable phosphorylation sites at Ser106 and Ser108 within α-helix 4 that affect its functional properties . Understanding ACBD6 contributes to broader knowledge of protein modification pathways and lipid metabolism regulation, making it an important target for both basic and translational research.

What applications are ACBD6 antibodies validated for?

ACBD6 antibodies have been validated for multiple research applications across different experimental systems. The primary validated applications include:

These applications enable researchers to detect, localize, and quantify ACBD6 protein in various experimental contexts . When selecting an application, researchers should verify that their specific antibody has been validated for that particular technique with appropriate positive controls.

How should researchers select the appropriate ACBD6 antibody for their experiments?

When selecting an ACBD6 antibody, researchers should consider several critical parameters to ensure experimental success:

• Target region specificity: Various antibodies target different regions of ACBD6, including:

  • Internal regions (e.g., amino acids 121-170)

  • N-terminal regions (e.g., amino acids 52-78)

  • Full-length protein (amino acids 1-282)

• Species reactivity: Confirm the antibody recognizes ACBD6 in your experimental organism. Available antibodies show reactivity against:

  • Human ACBD6

  • Mouse ACBD6

  • Rat ACBD6

  • Some antibodies offer broader reactivity including horse, rabbit, pig, and monkey samples

• Application compatibility: Verify validation data for your specific application (WB, ELISA, IHC, etc.)

• Host species and clonality: Most available ACBD6 antibodies are rabbit polyclonal, but considering the host species is important for avoiding cross-reactivity in multi-color staining experiments

• Post-translational modification sensitivity: For studies involving phosphorylated ACBD6 (particularly at Ser106 and Ser108), determine whether the antibody's binding is affected by these modifications

The selection process should include reviewing validation data for each antibody candidate and considering the specific experimental requirements.

What controls are essential when working with ACBD6 antibodies?

Implementing appropriate controls is crucial for ensuring reliable results with ACBD6 antibodies:

• Positive controls:

  • Cell lines known to express ACBD6 (e.g., HepG2, HUVEC)

  • Recombinant ACBD6 protein

  • Tissues with documented ACBD6 expression

• Negative controls:

  • Peptide competition assays using the immunizing peptide (e.g., synthetic peptide from the internal region of human ACBD6)

  • Isotype controls (e.g., rabbit IgG for rabbit polyclonal antibodies)

  • ACBD6 knockdown/knockout samples (if available)

• Technical controls:

  • Secondary antibody-only controls to assess background

  • Loading controls for Western blots (β-actin, GAPDH, etc.)

  • Concentration-matched non-specific IgG controls

Including these controls allows researchers to distinguish specific antibody binding from background or non-specific signals, significantly enhancing data reliability and interpretation accuracy.

How do phosphorylation states affect ACBD6 antibody recognition and experimental design?

The phosphorylation of Ser106 and Ser108 within α-helix 4 of the ACB domain significantly impacts ACBD6 function and potentially antibody recognition . When designing experiments to study phosphorylated ACBD6:

• Antibody selection considerations:

  • Determine if your antibody's epitope includes or is near Ser106/Ser108

  • Verify whether phosphorylation alters antibody binding affinity

  • Consider using phospho-specific antibodies for direct detection of phosphorylated forms

• Sample preparation protocol modifications:

  • Include phosphatase inhibitors in lysis buffers to preserve phosphorylation states

  • Consider lambda phosphatase treatment as a negative control

  • For recombinant systems, use phosphomimetic mutations (S106D/E, S108D/E) or the phosphorylation system described in research (using E. coli strain BL21(DE3)ΔserB with pKW2.EF.Sep)

• Experimental validation approaches:

  • Compare antibody recognition patterns before and after phosphatase treatment

  • Use mass spectrometry to verify phosphorylation states in parallel

  • Implement mutational analysis with non-phosphorylatable alanine substitutions

These considerations are essential for accurately interpreting results when studying how phosphorylation affects ACBD6 function in acyl-CoA binding and NMT regulation.

What are the methodological considerations for studying ACBD6-NMT interactions?

Research has demonstrated that ACBD6 interacts with and regulates both NMT1 and NMT2, with important implications for N-myristoylation processes . When investigating these interactions:

• Protein-protein interaction detection methods:

  • Mammalian two-hybrid assays: Successfully used for studying ACBD6-NMT interactions using pBIND vector (for NMT) and pACT vector (for ACBD6)

  • Co-immunoprecipitation: Optimize lysis conditions to preserve native protein complexes

  • Pull-down assays: Using purified components to verify direct interactions

• Functional analysis approaches:

  • NMT activity assays in the presence/absence of ACBD6

  • Competition experiments with different acyl-CoA species (C12-CoA, C14-CoA, C16-CoA)

  • Studies with ACBD6 mutants deficient in acyl-CoA binding

• Controls and validation:

  • Include wild-type and ligand-binding deficient ACBD6 mutants

  • Test interactions with both human NMT (hNMT) and Plasmodium falciparum NMT (PfNMT)

  • Implement concentration-dependency experiments for quantitative analysis

This methodological framework enables researchers to comprehensively characterize the molecular mechanisms underlying ACBD6's role in regulating myristoyltransferase activity and substrate specificity.

How can researchers quantitatively assess ACBD6-acyl-CoA binding using antibody-based techniques?

For quantitative analysis of ACBD6-acyl-CoA interactions, researchers can implement several antibody-dependent approaches:

• Radioactive binding assays:

  • Incubate purified ACBD6 with [14C]C18:1-CoA as described in research protocols

  • Use ACBD6 antibodies for immunoprecipitation before measuring bound radioactivity

  • Implement competition experiments with unlabeled acyl-CoA species

• Displacement analysis procedure:

  • Purify [14C]C18:1-CoA/ACBD6 complexes using Ni-NTA resin pull-down

  • Challenge with competing acyl-CoA species (e.g., C24-CoA)

  • Quantify remaining bound [14C]C18:1-CoA after secondary pull-down

• Antibody-based binding analysis:

  • Develop ELISA-based methods to detect ACBD6-acyl-CoA complexes

  • Use antibodies that don't interfere with the acyl-CoA binding site

  • Implement concentration gradients for affinity determinations

For accurate quantitation, researchers should:

• Perform protein quantification using validated methods

• Include multiple technical and biological replicates

• Develop standard curves using known concentrations of purified components

• Apply appropriate statistical analyses to binding data

These approaches enable detailed characterization of ACBD6's acyl-CoA binding properties and how they relate to its biological functions.

What are the optimized Western blotting protocols for ACBD6 detection?

For optimal ACBD6 detection via Western blotting, researchers should follow this detailed protocol:

• Sample preparation:

  • Lyse cells in RIPA or NP-40 buffer containing protease inhibitors

  • For phosphorylation studies, include phosphatase inhibitors

  • Quantify protein concentration (BCA or Bradford assay)

  • Denature samples in Laemmli buffer (95°C for 5 minutes)

• Gel electrophoresis parameters:

  • Use 10-12% SDS-PAGE for optimal separation of ACBD6 (31 kDa)

  • Load 20-40 μg total protein per lane

  • Include molecular weight markers spanning 15-50 kDa range

• Transfer and blocking optimization:

  • Transfer to PVDF membrane (wet transfer: 100V for 60 minutes)

  • Block with 5% non-fat dry milk or BSA in TBST for 1 hour

• Antibody incubation conditions:

  • Primary antibody: Dilute ACBD6 antibody 1:500-1:1000 in blocking buffer

  • Incubate overnight at 4°C with gentle rocking

  • Secondary antibody: Anti-rabbit HRP (1:5000-1:10000) for 1 hour at room temperature

• Detection and troubleshooting:

  • Use ECL substrate appropriate for expected signal intensity

  • Optimize exposure time to avoid saturation

  • For weak signals, consider enhanced chemiluminescence substrates

  • For high background, increase washing stringency or further dilute antibodies

Following this optimized protocol will maximize detection sensitivity while minimizing non-specific background, resulting in clean, interpretable Western blot data for ACBD6.

What technical approaches can resolve detection challenges in complex samples?

When working with ACBD6 antibodies in complex samples like tissue sections or heterogeneous cell populations, researchers may encounter several technical challenges:

• Signal-to-noise optimization strategies:

  • Antibody titration: Test dilution series to find optimal concentration

  • Blocking optimization: Compare different blocking agents (milk, BSA, commercial blockers)

  • Sample pre-treatment: Consider antigen retrieval methods for fixed tissues

  • Signal amplification: Implement tyramide signal amplification for low-abundance detection

• Specificity validation approaches:

  • Peptide competition: Pre-incubate antibody with synthetic peptide corresponding to the immunizing sequence (e.g., amino acids 121-170)

  • Multiple antibody comparison: Use antibodies targeting different ACBD6 epitopes

  • Genetic validation: Include ACBD6 knockdown/knockout samples

• Complex sample preparation considerations:

  • Tissue fixation comparison: Test multiple fixatives to optimize epitope preservation

  • Permeabilization optimization: Adjust detergent type/concentration based on subcellular localization

  • Autofluorescence reduction: Implement Sudan Black B treatment or spectral unmixing

• Advanced detection approaches:

  • Super-resolution microscopy for precise subcellular localization

  • Mass cytometry for single-cell protein quantification in heterogeneous samples

  • Proximity ligation assay for detecting ACBD6 interactions in situ

These technical approaches enable researchers to overcome common challenges when studying ACBD6 in complex biological samples, yielding more reliable and interpretable results.

How do different ACBD6 antibodies compare in sensitivity and specificity?

Available ACBD6 antibodies exhibit distinct characteristics that should inform selection for specific research applications:

Specificity considerations:

• Antibodies targeting the internal region generally show robust detection across multiple species

• Epitope availability may differ between applications (native vs. denatured conditions)

• Cross-reactivity profiles should be assessed experimentally for each application

• Validation data from manufacturers should be critically evaluated with independent verification

When multiple antibodies are available, researchers should consider testing several to identify the optimal reagent for their specific experimental system and application.

How does ACBD6 antibody performance compare across different experimental systems?

ACBD6 antibody performance can vary significantly across experimental systems:

• Cell culture systems comparison:

  • Cell lines: Strong detection in HepG2 and HUVEC cells, with clean bands at expected molecular weight

  • Primary cells: May require optimization due to potentially lower expression levels

  • Transfected/overexpression systems: High sensitivity but potential for artifacts

• Tissue section analysis considerations:

  • Fixed tissues: Epitope accessibility affected by fixation method and duration

  • Fresh frozen samples: Often better epitope preservation but poorer morphology

  • Species differences: Human ACBD6 detection typically more robust than other species

• Subcellular localization detection comparison:

  • Cytoplasmic ACBD6: Generally accessible with standard permeabilization protocols

  • Membrane-associated forms: May require specialized permeabilization conditions

  • Nuclear localization: Often requires optimization of nuclear membrane permeabilization

• Quantitative application performance:

  • Western blotting: Provides reliable quantification when properly controlled

  • ELISA: Offers higher throughput but requires careful standard curve development

  • Imaging-based quantification: Enables spatial information but requires rigorous normalization

This comparative analysis enables researchers to anticipate potential challenges and implement appropriate optimizations when adapting ACBD6 detection methods across different experimental systems.

How can researchers troubleshoot weak or absent ACBD6 signal in Western blotting?

When facing weak or absent ACBD6 signal in Western blotting experiments, researchers should systematically investigate potential causes:

• Sample preparation issues:

  • Protein degradation: Ensure complete protease inhibition during lysis

  • Protein denaturation: Verify heating conditions (95°C for 5 minutes)

  • Low expression: Increase loading amount (up to 60-80 μg total protein)

  • Extraction efficiency: Try alternative lysis buffers (RIPA vs. NP-40)

• Technical optimization approaches:

  • Primary antibody: Test concentration range (1:250 to 1:2000)

  • Incubation time: Extend to 48 hours at 4°C for weak signals

  • Detection system: Switch to high-sensitivity ECL substrates

  • Membrane type: Compare PVDF vs. nitrocellulose for optimal binding

• Systematic optimization strategy:

  • Start with positive control samples (HepG2 cells)

  • Perform dot blots to verify antibody functionality

  • Test multiple antibodies targeting different ACBD6 epitopes

  • Consider immunoprecipitation followed by Western blotting for enrichment

• Data from troubleshooting experiments:

  • Document signal-to-background ratios at different antibody dilutions

  • Compare transfer efficiency with reversible protein stains

  • Quantify loading control expression to normalize samples

By systematically investigating these parameters, researchers can identify and address the specific factors limiting ACBD6 detection in their Western blotting experiments.

What strategies address non-specific binding and high background with ACBD6 antibodies?

When encountering non-specific binding or high background with ACBD6 antibodies, implement these evidence-based troubleshooting strategies:

• Blocking optimization approaches:

  • Compare blocking agents: 5% BSA often reduces background compared to milk for phospho-epitopes

  • Extended blocking: Increase duration from 1 hour to overnight at 4°C

  • Specialized blockers: Test commercial blockers designed to reduce non-specific binding

• Antibody optimization:

  • Further dilution: Test more dilute antibody preparations (1:1000 to 1:5000)

  • Pre-adsorption: Incubate antibody with negative control lysates

  • Alternative antibody: Test antibodies targeting different ACBD6 epitopes

• Washing protocol modifications:

  • Increased stringency: Add 0.1-0.3% SDS to TBST wash buffer

  • Extended washing: Increase number of washes (5-6 times) and duration (10-15 minutes each)

  • Temperature adjustment: Perform washes at 37°C rather than room temperature

• Technical modifications:

  • Secondary antibody: Reduce concentration or switch to highly cross-adsorbed versions

  • Detection system: Use chromogenic rather than chemiluminescent detection for high background

  • Membrane handling: Ensure membranes never dry during processing

These strategies directly address the most common causes of non-specific binding and high background, allowing researchers to obtain cleaner, more interpretable data when working with ACBD6 antibodies.

What future directions are emerging for ACBD6 antibody applications in research?

The field of ACBD6 research is evolving rapidly, with several promising directions for antibody applications:

• Advanced spatiotemporal analysis:

  • Live-cell imaging using antibody fragments or nanobodies

  • Super-resolution microscopy for precise subcellular localization

  • Correlative light and electron microscopy for ultrastructural context

• Functional studies linking ACBD6 to disease mechanisms:

  • Investigation of ACBD6's role in parasite-host interactions with Plasmodium

  • Analysis of ACBD6 in metabolic diseases given its role in acyl-CoA metabolism

  • Therapeutic targeting of ACBD6-NMT interactions

• Multi-omics integration approaches:

  • Combining antibody-based proteomics with lipidomics analysis

  • Correlation of ACBD6 post-translational modifications with functional outcomes

  • Systems biology approaches to position ACBD6 in broader metabolic networks

• Novel antibody-dependent technologies:

  • Proximity-dependent biotinylation to map ACBD6 interactomes

  • Antibody-based protein degradation (PROTAC) strategies

  • Single-molecule tracking of ACBD6 dynamics

These emerging directions highlight the continuing importance of well-characterized, highly specific ACBD6 antibodies for advancing our understanding of this protein's multifaceted roles in cellular biology and potential therapeutic applications.

What consensus best practices should researchers follow when designing ACBD6 antibody-based experiments?

Based on current research and technical considerations, these consensus best practices are recommended for ACBD6 antibody-based experiments:

• Experimental design principles:

  • Include appropriate positive and negative controls for each experiment

  • Validate antibodies in your specific experimental system before conducting main studies

  • Implement biological replicates (minimum n=3) for all quantitative analyses

  • Use multiple antibodies or detection methods for critical findings

• Technical implementation guidelines:

  • Western blotting: Use 1:500-1:1000 dilution of ACBD6 antibodies with overnight incubation at 4°C

  • ELISA: Implement 1:5000 dilution for optimal signal-to-noise ratio

  • Immunofluorescence: Include appropriate counterstains for contextual information

  • For phosphorylation studies: Always include phosphatase inhibitors during sample preparation

• Data analysis and reporting standards:

  • Include complete methodological details (antibody catalog numbers, dilutions, incubation conditions)

  • Provide uncropped blot images for Western blot data

  • Quantify results with appropriate statistical analysis

  • Consider the biological context when interpreting antibody-based findings

• Quality control checkpoints:

  • Periodically verify antibody performance with positive control samples

  • Include lot-to-lot validation for critical studies

  • Document optimization parameters for reproducibility